In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plus Therapeutics, Inc.

http://www.plustherapeutics.com

Latest From Plus Therapeutics, Inc.

Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds

Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.

Financing Innovation

Solutions Exist To Regenerative Medicine's Most Pressing Manufacturing Challenges

Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.

Manufacturing Gene Therapy

Advanz Gets European Heft, Portfolio Assets In Correvio Buyout

Deal Snapshot: Building portfolio and commercial infrastructure in Europe, Advanz gets both at a modest price in acquiring Correvio.

M & A Business Strategies

Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell

Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.

M & A Regenerative Medicine
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Azaya Therapeutics, Inc.
    • Cytori Therapeutics, Inc.
UsernamePublicRestriction

Register